Long-lived CD44+ tumour-initiating cells can selectively evade host immune responses and provide a rationale for targeting the PD-1 pathway in the adjuvant therapy setting of SCCHN [55]. This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.